Loading organizations...
MorphoSys develops and utilizes advanced antibody, protein, and peptide technologies for the discovery and development of therapeutic drug candidates. The company focuses on creating fully human antibodies, employing proprietary platforms such as CysDisplay enhanced phage display technology and the Ylanthia antibody library. This technological expertise enables the identification and optimization of novel biological therapeutics, addressing various disease areas through precision engineering.
The company was founded in the summer of 1992 by Dr. Simon Moroney, who also served as CEO, and his team. Their foundational insight centered on harnessing phage display technology to generate highly specific and fully human antibodies, overcoming limitations of previous antibody generation methods. This innovative approach laid the groundwork for developing a robust pipeline of potential therapies.
MorphoSys's products are primarily utilized within its own pipeline and through partnerships with other pharmaceutical companies, aiming to bring innovative drug candidates to patients. The company's vision is to translate its deep understanding of antibody biology into effective treatments, ultimately improving patient outcomes and contributing to advancements in medical science.
Key people at MorphoSys.
MorphoSys was founded in 1992 by Andreas Pluckthun (Co-Founder).
MorphoSys was founded in 1992 by Andreas Pluckthun (Co-Founder).
MorphoSys has 1 tracked investment across 1 company. The latest tracked deal is $6.2M Series A in Lanthio Pharma in November 2012.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 28, 2012 | Lanthio Pharma | $6.2M Series A | BioGeneration Ventures, INKEF Capital | Hanzepoort |
Key people at MorphoSys.
